AKUMS — Akums Drugs and Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- IN₹81.24bn
- IN₹78.43bn
- IN₹41.78bn
- 59
- 18
- 42
- 32
Annual income statement for Akums Drugs and Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | PROSPECTUS |
| Standards: | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 27,226 | 36,719 | 36,548 | 41,782 |
| Cost of Revenue | ||||
| Gross Profit | 9,304 | 11,838 | 11,999 | 14,352 |
| Selling / General / Administrative Expenses | ||||
| Depreciation and Amortization | ||||
| Unusual Expense / Income | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 25,106 | 33,724 | 35,375 | 38,478 |
| Operating Profit | 2,120 | 2,995 | 1,174 | 3,304 |
| Gain / Loss on Sale of Assets | ||||
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | 1,723 | -1,932 | 1,503 | -453 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | 1,234 | -2,509 | 978 | 7.9 |
| Minority Interest | ||||
| Net Income Before Extraordinary Items | ||||
| Net Income | 1,227 | -2,525 | 949 | -40.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | 1,227 | -2,525 | 949 | -40.4 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | 8.27 | -15.5 | 8.83 | 0.826 |
| Dividends per Share |